A patient presents with shortness of breath and wheezing. Upon auscultation, you notice a prolonged expiratory phase. What condition is most likely causing these symptoms?

A. Pulmonary Embolism: This condition involves an acute mechanical obstruction of the pulmonary vasculature, usually by a thrombus. While it causes sudden shortness of breath and tachypnea, it does not typically produce a prolonged expiratory phase or diffuse wheezing. Its hallmark is a ventilation-perfusion mismatch without primary airway obstruction.

B. Asthma: This obstructive airway disease is characterized by reversible bronchoconstriction, mucosal edema, and mucus hypersecretion. The narrowed diameter of the lower airways increases resistance, making it particularly difficult for air to exit the lungs during expiration. This physiological resistance results in the classic prolonged expiratory phase and audible wheezing.

C. Pleural Effusion: An accumulation of fluid in the pleural space compresses the underlying lung tissue, leading to diminished breath sounds and dullness to percussion. It acts as an extrinsic restrictive process rather than an intrinsic obstructive one. It does not typically cause the prolonged expiratory whistling characteristic of small airway narrowing.

D. Pneumonia: This inflammatory process involves the consolidation of the alveoli with exudate and debris, which impairs gas exchange but does not primarily obstruct the small airways. Auscultatory findings usually include crackles or bronchial breath sounds over the area of consolidation. It does not cause the diffuse expiratory delay seen in bronchospastic disorders.

A. Increase the dose of the decongestant: Escalating the dosage of a topical sympathomimetic would exacerbate the physiological dependence of the nasal mucosa on the drug. This would worsen rhinitis medicamentosa, a condition where the vasculature remains chronically dilated without the stimulant. Increasing the dose leads to a cycle of progressively severe mucosal edema.

B. Add mucolytics to the treatment regimen: Mucolytics function by breaking disulfide bonds in mucus to decrease its viscosity and facilitate clearance from the respiratory tract. While helpful for clearing secretions, they do not address the underlying localized vasodilation and tissue swelling characteristic of rebound congestion. They provide no mechanism for restoring normal nasal vascular tone.

C. Stop using decongestants and consult the provider: The primary treatment for rhinitis medicamentosa is the immediate cessation of the causative intranasal vasoconstrictor to allow the nasal mucosa to recover. A healthcare provider can then prescribe intranasal corticosteroids to manage the resulting inflammation and transition the patient to a safer therapy. This approach addresses the root cause of the congestion.

D. Switch to antihistamines: Antihistamines are primarily indicated for allergic rhinitis by blocking the H1 receptor-mediated response to allergens. They do not possess the vasoconstrictive properties needed to counteract the profound mucosal engorgement seen in rebound congestion from decongestant overuse. They are ineffective for treating drug-induced nasal vascular dysfunction.